NCT05070637

Brief Summary

This study will study circulating tumor cell (CTC) release during laparoscopic radical nephrectomy (LRN) for RCC. The main objective is to determine if CTC release can be reduced during RN by using a no-touch technique, with an early renal pedicle ligation. The investigators also aim to describe the CTC profile in terms of CTC count (CTCn), epithelial/mesenchymal status, and CTC cellular features in renal cell carcinoma (RCC) patients, stratified by "primary tumor, regional nodes, metastasis" (TNM) staging, histological subtype, and other clinical and radiological features. Patients undergoing RN will enter a two-arm prospective single-center randomized controlled trial (RCT), comparing a no-touch RN technique, with direct pedicle ligation (Group A) vs. the more conventional approach of kidney traction and manipulation to reach the renal pedicle before its ligation (Group B). A microfluidic size-based CTC isolation device will be used to capture and count CTCs from peripheral blood samples of these patients. CTCs will be identified by staining with antibodies to cytokeratin 8/18, vimentin, 4',6-diamidino-2-phenylindole (DAPI), and cluster of differentiation antigen 45 (CD45). CTC release will be correlated with the disease-free survival (DFS), and overall survival (OS). The investigators will determine if CTC reducing no-touch radical nephrectomy technique improves these hard outcomes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 26, 2021

Completed
1 day until next milestone

Study Start

First participant enrolled

September 27, 2021

Completed
10 days until next milestone

First Posted

Study publicly available on registry

October 7, 2021

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 18, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 18, 2022

Completed
Last Updated

November 14, 2022

Status Verified

November 1, 2022

Enrollment Period

8 months

First QC Date

September 26, 2021

Last Update Submit

November 10, 2022

Conditions

Keywords

circulating tumor cellrenal cell carcinomaradical nephrectomyno-touch nephrectomy

Outcome Measures

Primary Outcomes (3)

  • Circulating tumor cell count - intra-operative

    CTC count in peripheral blood after tumor specimen extraction

    Intra-operative

  • Circulating tumor cell count - D1

    CTC count in peripheral blood at post-operative day 1

    Post-operative day 1

  • Circulating tumor cell count - D30

    CTC count in peripheral blood at post-operative day 30

    Post-operative day 30

Secondary Outcomes (2)

  • Overall survival

    3 year

  • Disease free survival

    3 year

Study Arms (3)

No-touch laparoscopic radical nephrectomy

EXPERIMENTAL

Group A patients will undergo a no-touch laparoscopic radical nephrectomy, with the dissection being done through the Gerota's fascia plane until exposure of the corresponding great vessel (vena cava on the right side, and aorta on the left side) is obtained. The renal pedicle will be directly isolated, and ligated using Weck® clips with no kidney manipulation.

Procedure: No-touch laparoscopic radical nephrectomy

Conventional laparoscopic radical nephrectomy

ACTIVE COMPARATOR

Group B patients will undergo a conventional laparoscopic radical nephrectomy approach, starting with opening of the Gerota's fascia, identification of the ureter, traction on the peri-renal fat below the ureter while dissecting cephalad until the renal pedicle is reached. The renal pedicle will then be isolated while maintaining traction on the kidney, and peri-renal fat, and ligated using Weck® clips.

Procedure: Conventional laparoscopic radical nephrectomy

Laparoscopic total nephrectomy control arm

OTHER

Control arm in which a laparoscopic total nephrectomy will be performed in patients with hypo-functioning kidneys, and no renal cell carcinoma.

Procedure: Laparoscopic total nephrectomy control arm

Interventions

We aim to determine if a laparoscopic no-touch nephrectomy with an early renal pedicle ligation can decrease CTC release during surgery.

No-touch laparoscopic radical nephrectomy

Conventional laparoscopic radical nephrectomy, which implies manipulation of the kidney, opening of the Gerota's fascia, and manipulation of peri-nephric fat during dissection, and renal pedicle isolation.

Conventional laparoscopic radical nephrectomy

Control arm in which a laparoscopic total nephrectomy will be performed in non-cancer patients.

Laparoscopic total nephrectomy control arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Renal mass on renal imaging compatible with kidney cancer
  • Indication for laparoscopic radical nephrectomy

You may not qualify if:

  • History of other cancer (carcinoma)
  • Previous systemic therapy for renal cell carcinoma
  • human immunodeficiency virus (HIV) positive
  • Hepatitis C virus (HCV) positive
  • hepatitis B virus (HBV) positive

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Urology Department - Hospital de Santa Maria

Lisbon, Lisbon District, 1649-035, Portugal

Location

MeSH Terms

Conditions

Carcinoma, Renal CellNeoplastic Cells, Circulating

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsKidney NeoplasmsUrologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital DiseasesNeoplasm MetastasisNeoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Tito P Leitão, MD

    Faculdade de Medicina da Universidade de Lisboa

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

September 26, 2021

First Posted

October 7, 2021

Study Start

September 27, 2021

Primary Completion

May 18, 2022

Study Completion

May 18, 2022

Last Updated

November 14, 2022

Record last verified: 2022-11

Locations